A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.

A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.

The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

The present subject matter relates to light-activatable polymeric nanoparticles (NPs) for the transportation and release of an active substance, methods for obtain said particles and their uses. A light-activatable nanoparticle for the transportation and release of an active substance, comprising a polycation preferably a polimer polycation, a polyanion and a light-sensitive photochrome attached to the polycation or the polyanion, wherein said photochrome is hydrophobic and suitable to photo-cleave when activated by an irradiation source, generating a negative charge and releasing the active substance. Light-activatable. The disclosure subject matter shows that NPs are a highly efficient drug delivery system to primary leukemic cells based on opto-nanomedicine system. Therefore, the present disclosure is useful for remote control in the release of biomolecules with spatio-temporal resolution with applications in the areas of general therapeutic and regenerative medicine applications.

The present subject matter relates to light-activatable polymeric nanoparticles (NPs) for the transportation and release of an active substance, methods for obtain said particles and their uses. A light-activatable nanoparticle for the transportation and release of an active substance, comprising a polycation preferably a polimer polycation, a polyanion and a light-sensitive photochrome attached to the polycation or the polyanion, wherein said photochrome is hydrophobic and suitable to photo-cleave when activated by an irradiation source, generating a negative charge and releasing the active substance. Light-activatable. The disclosure subject matter shows that NPs are a highly efficient drug delivery system to primary leukemic cells based on opto-nanomedicine system. Therefore, the present disclosure is useful for remote control in the release of biomolecules with spatio-temporal resolution with applications in the areas of general therapeutic and regenerative medicine applications.

A medical salve designed to address and treat bedsore, also known as decubitus ulcers. The medical salve includes a plurality of ingredients that each has their own unique beneficial properties. The plurality of ingredients includes a quantity of antibiotic powder composition, a quantity of antifungal powder, a quantity of topical steroid powder, a quantity of ethoxydiglycol, a quantity of silver sulfadiazine cream, a quantity of retinoic acid powder, a quantity of dimethyl sulfoxide solution, and a quantity of oleo plasticized base. The antibiotic powder composition, the antifungal powder, the topical steroid powder, the dimethyl sulfoxide solution, and the retinoic acid are the main active ingredients in the medical salve that are designed to address the symptoms of bedsores as well as expedite the healing process. The silver sulfadiazine cream, the ethoxydiglycol, and the oleo plasticized base are used as the base materials for medical salve.

A medical salve designed to address and treat bedsore, also known as decubitus ulcers. The medical salve includes a plurality of ingredients that each has their own unique beneficial properties. The plurality of ingredients includes a quantity of antibiotic powder composition, a quantity of antifungal powder, a quantity of topical steroid powder, a quantity of ethoxydiglycol, a quantity of silver sulfadiazine cream, a quantity of retinoic acid powder, a quantity of dimethyl sulfoxide solution, and a quantity of oleo plasticized base. The antibiotic powder composition, the antifungal powder, the topical steroid powder, the dimethyl sulfoxide solution, and the retinoic acid are the main active ingredients in the medical salve that are designed to address the symptoms of bedsores as well as expedite the healing process. The silver sulfadiazine cream, the ethoxydiglycol, and the oleo plasticized base are used as the base materials for medical salve.

A medical salve designed to address and treat bedsore, also known as decubitus ulcers. The medical salve includes a plurality of ingredients that each has their own unique beneficial properties. The plurality of ingredients includes a quantity of antibiotic powder composition, a quantity of antifungal powder, a quantity of topical steroid powder, a quantity of ethoxydiglycol, a quantity of silver sulfadiazine cream, a quantity of retinoic acid powder, a quantity of dimethyl sulfoxide solution, and a quantity of oleo plasticized base. The antibiotic powder composition, the antifungal powder, the topical steroid powder, the dimethyl sulfoxide solution, and the retinoic acid are the main active ingredients in the medical salve that are designed to address the symptoms of bedsores as well as expedite the healing process. The silver sulfadiazine cream, the ethoxydiglycol, and the oleo plasticized base are used as the base materials for medical salve.

Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.